期刊
SCIENTIFIC REPORTS
卷 12, 期 1, 页码 -出版社
NATURE PORTFOLIO
DOI: 10.1038/s41598-022-06774-8
关键词
-
资金
- National Research Council of Sri Lanka Investigator Driven Research Grant [18-030]
Hydroxyurea can increase fetal hemoglobin percentage and reduce erythropoietic stress in patients with transfusion-dependent beta-thalassaemia. It can also reduce the transfusion burden in approximately 40% of patients. The response to hydroxyurea is higher in patients with HbE beta-thalassaemia genotype and Xmn1 polymorphism of the gamma-globin gene.
Hydroxyurea is an antimetabolite drug that induces fetal haemoglobin in sickle cell disease. However, its clinical usefulness in beta-thalassaemia is unproven. We conducted a randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of hydroxyurea in transfusion-dependent beta-thalassaemia. Sixty patients were assigned 1:1 to oral hydroxyurea 10-20 mg/kg/day or placebo for 6 months by stratified block randomisation. Hydroxyurea treatment did not alter the blood transfusion volume overall. However, a significantly higher proportion of patients on hydroxyurea showed increases in fetal haemoglobin percentage (89% vs. 59%; p < 0.05) and reductions in erythropoietic stress as measured by soluble transferrin receptor concentration (79% vs. 40%; p < 0.05). Based on fetal haemoglobin induction (> 1.5%), 44% of patients were identified as hydroxyurea-responders. Hydroxyurea-responders, required significantly lower blood volume (77 +/- SD27ml/kg) compared to hydroxyurea-non-responders (108 +/- SD24ml/kg; p < 0.01) and placebo-receivers (102 +/- 28ml/kg; p < 0.05). Response to hydroxyurea was significantly higher in patients with HbE beta-thalassaemia genotype (50% vs. 0%; p < 0.01) and Xmn1 polymorphism of the gamma-globin gene (67% vs. 27%; p < 0.05). We conclude that oral hydroxyurea increased fetal haemoglobin percentage and reduced erythropoietic stress of ineffective erythropoiesis in patients with transfusion-dependent beta-thalassaemia. Hydroxyurea reduced the transfusion burden in approximately 40% of patients. Response to hydroxyurea was higher in patients with HbE beta-thalassaemia genotype and Xmn1 polymorphism of the gamma-globin gene.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据